<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03671018</url>
  </required_header>
  <id_info>
    <org_study_id>GO40516</org_study_id>
    <secondary_id>2018-001141-13</secondary_id>
    <nct_id>NCT03671018</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma</brief_title>
  <official_title>An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of&#xD;
      intravenous mosunetuzumab in combination with polatuzumab vedotin in participants with&#xD;
      diffuse large B-cell lymphoma (DLBCL) and in participants with follicular lymphoma (FL). It&#xD;
      will consist of a dose finding portion followed by an expansion phase for second line or&#xD;
      later (2L+) participants with relapsed or refractory (R/R) DLBCL and 2L+ R/R FL. In addition,&#xD;
      subcutaneous mosunetuzumab in combination with polatuzumab vedotin will be evaluated in&#xD;
      participants with at least 2 prior lines of systemic therapy for the treatment of R/R mantle&#xD;
      cell lymphoma (MCL).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 25, 2018</start_date>
  <completion_date type="Anticipated">April 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of Mosunetuzumab in Combination with Polatuzumab Vedotin</measure>
    <time_frame>Cycle 1 to Cycle 2 (cycle length = 21 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase II Dose of Mosunetuzumab in Combination with Polatuzumab Vedotin</measure>
    <time_frame>Cycle 1 to Cycle 2 (cycle length = 21 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events (AE)</measure>
    <time_frame>Baseline through approximately 90 days after last study treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Best Objective Response Rate (ORR), Defined as CR or Partial Response (PR) at any Time, Based on PET-CT and/or CT Scan, as Determined by the Independent Review Committee (IRC) using Standard Criteria for NHL</measure>
    <time_frame>Baseline up to approximately 60 months (assessed at screening and then every 3 months for the first year, then every 6 months until disease progression, start of new anti-cancer therapy, or withdrawal)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best ORR (CR or PR at any Time) Based on PET-CT and/or CT Scan, as Determined by the Investigator Using Standard Criteria for NHL</measure>
    <time_frame>Baseline up to approximately 60 months (assessed at screening and then every 3 months for the first year, then every 6 months until disease progression, start of new anti-cancer therapy, or withdrawal)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best CR Rate on Study Based on PET-CT, and/or CT Scan, as Determined by the Investigator and IRC Using Standard Criteria for NHL</measure>
    <time_frame>Baseline up to approximately 60 months (assessed at screening and then every 3 months for the first year, then every 6 months until disease progression, start of new anti-cancer therapy, or withdrawal)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR Rate at the Time of Primary Response Assessment (PRA) Based on PET-CT, as Determined by the Investigator and IRC Using Standard Criteria for NHL</measure>
    <time_frame>Cycle 8 completion (participants receiving mosunetuzumab), or 5-7 weeks after Cycle 6 (polatuzumab+bendamustine+rituximab participants) (Cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR, Defined as CR or PR, at PRA Based on PET-CT as Determined by the Investigator and IRC Using Standard Criteria for NHL</measure>
    <time_frame>Cycle 8 completion (participants receiving mosunetuzumab), or 5-7 weeks after Cycle 6 (polatuzumab+bendamustine+rituximab participants) (Cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) as Determined by the Investigator and IRC Using Standard Criteria for NHL</measure>
    <time_frame>From the first occurrence of a documented response to disease progression, relapse, or death from any cause, whichever occurs first (up to approximately 60 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) as Determined by the Investigator and IRC Using Standard Criteria for NHL</measure>
    <time_frame>From time of first study treatment to the first occurrence of disease progression, relapse, or death from any cause, whichever occurs first (up to approximately 60 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival (EFS) as Determined by the Investigator and IRC Using Standard Criteria for NHL</measure>
    <time_frame>From time of first study treatment to the first occurrence of disease progression, relapse, initiation of new anti-lymphoma treatment (NALT), or death from any cause, whichever occurs first (up to approximately 60 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From time of first study treatment to death from any cause (up to approximately 60 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Drug Antibodies (ADAs) to Mosunetuzumab</measure>
    <time_frame>At pre-defined intervals from C1D1 through approximately 90 days after the last study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADAs to Polatuzumab Vedotin</measure>
    <time_frame>At pre-defined intervals from C1D1 through approximately 90 days after the last study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mosunetuzumab Serum Concentration</measure>
    <time_frame>At pre-defined intervals from C1D1 through approximately 90 days after the last study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">262</enrollment>
  <condition>B-cell Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Dose Finding</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive mosunetuzumab in combination with polatuzumab vedotin. Dose finding will be guided by the observed incidence of dose-limiting toxicities (DLTs) at each dose level.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mosunetuzumab + Polatuzumab Vedotin 2L+ R/R FL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with at least one line of prior therapy (2L+) and that have relapsed or refractory (R/R) follicular lymphoma (FL) will receive mosunetuzumab + polatuzumab vedotin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mosunetuzumab + Polatuzumab Vedotin 2L+R/R DLBCL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2L+ participants with R/R diffuse large B-cell lymphoma will receive mosunetuzumab + polatuzumab vedotin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mosunetuzumab SC + Polatuzumab Vedotin 3L+R/R MCL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with at least 2 lines of prior therapy (3L+) will receive subcutaneous (SC) mosunetuzumab + polatuzumab vedotin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mosunetuzumab (IV)</intervention_name>
    <description>Participants will receive intravenous (IV) mosunetuzumab.</description>
    <arm_group_label>Dose Finding</arm_group_label>
    <arm_group_label>Mosunetuzumab + Polatuzumab Vedotin 2L+ R/R FL</arm_group_label>
    <arm_group_label>Mosunetuzumab + Polatuzumab Vedotin 2L+R/R DLBCL</arm_group_label>
    <other_name>BTCT4465A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mosunetuzumab (SC)</intervention_name>
    <description>Participants will receive subcutaneous (SC) mosunetuzumab.</description>
    <arm_group_label>Mosunetuzumab SC + Polatuzumab Vedotin 3L+R/R MCL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polatuzumab vedotin</intervention_name>
    <description>Participants will receive IV polatuzumab vedotin.</description>
    <arm_group_label>Dose Finding</arm_group_label>
    <arm_group_label>Mosunetuzumab + Polatuzumab Vedotin 2L+ R/R FL</arm_group_label>
    <arm_group_label>Mosunetuzumab + Polatuzumab Vedotin 2L+R/R DLBCL</arm_group_label>
    <arm_group_label>Mosunetuzumab SC + Polatuzumab Vedotin 3L+R/R MCL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Participants will receive IV tocilizumab as needed.</description>
    <arm_group_label>Dose Finding</arm_group_label>
    <arm_group_label>Mosunetuzumab + Polatuzumab Vedotin 2L+ R/R FL</arm_group_label>
    <arm_group_label>Mosunetuzumab + Polatuzumab Vedotin 2L+R/R DLBCL</arm_group_label>
    <arm_group_label>Mosunetuzumab SC + Polatuzumab Vedotin 3L+R/R MCL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  ECOG PS of 0, 1, or 2&#xD;
&#xD;
          -  Histologically confirmed FL, DLBCL, or MCL&#xD;
&#xD;
          -  Must have received at least one prior systemic treatment regimen containing an&#xD;
             anti-CD20-directed therapy for DLBCL or FL&#xD;
&#xD;
          -  For MCL, participants must have received at least two prior systemic treatment&#xD;
             regiments, which include 1) anti-CD20-directed therapy, 2) BTK inhibitor, and 3)&#xD;
             anthracycline or bendamustine&#xD;
&#xD;
          -  Relapsed to prior regimen(s) after having a documented history of response (complete&#xD;
             response [CR], CR unconfirmed [CRu], or partial response [PR]) of &gt;/= 6 months in&#xD;
             duration from completion of regimen(s); or, refractory to any prior regimen, defined&#xD;
             as no response to the prior therapy, or progression within 6 months of completion of&#xD;
             the last dose of therapy&#xD;
&#xD;
          -  Measurable disease, defined as at least one bi-dimensionally measurable nodal lesion,&#xD;
             defined as &gt; 1.5 cm in its longest dimension, or at least one bi-dimensionally&#xD;
             measurable extranodal lesion, defined as &gt; 1.0 cm in its longest dimension&#xD;
&#xD;
          -  Adequate hematologic, renal, and hepatic function&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with mosunetuzumab or other CD20-directed bispecific antibodies&#xD;
&#xD;
          -  Prior treatment with polatuzumab vedotin&#xD;
&#xD;
          -  Current &gt; Grade 1 peripheral neuropathy&#xD;
&#xD;
          -  Prior use of any monoclonal antibody, radioimmunoconjugate or antibody-drug conjugate&#xD;
             (ADC) within 4 weeks before first dose of study treatment&#xD;
&#xD;
          -  Treatment with any chemotherapeutic agent, or treatment with any other anti-cancer&#xD;
             agent (investigational or otherwise) within 4 weeks or 5 half-lives of the drug,&#xD;
             whichever is shorter, prior to first dose of study treatment&#xD;
&#xD;
          -  Treatment with radiotherapy within 2 weeks prior to the first dose of study treatment&#xD;
&#xD;
          -  Autologous stem-cell transplantation (SCT) within 100 days prior to first study&#xD;
             treatment administration&#xD;
&#xD;
          -  Prior treatment with chimeric antigen receptor T-cell (CAR-T) therapy within 30 days&#xD;
             before first study treatment administration&#xD;
&#xD;
          -  Prior allogeneic SCT&#xD;
&#xD;
          -  Prior solid organ transplantation&#xD;
&#xD;
          -  Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)&#xD;
&#xD;
          -  Patients with history of confirmed progressive multifocal leukoencephalopathy (PML)&#xD;
&#xD;
          -  Current or past history of central nervous system (CNS) lymphoma or CNS disease&#xD;
&#xD;
          -  History of autoimmune disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GO40516 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global.rochegenentechtrials@roche.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham School of Medicine</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>352331912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital - Anschutz Cancer Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York University Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh - Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232-1301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lifespan Cancer Institute</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH Jolimont - Lobbes (Jolimont)</name>
      <address>
        <city>Haine-Saint-Paul</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique St Pierre asbl</name>
      <address>
        <city>Ottignies</city>
        <zip>1340</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universite de Montreal - Hopital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saskatchewan Cancer Agency (SCA) - Saskatoon Cancer Centre (SCC)</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Catala d Oncologia Hospital Duran i Reynals</name>
      <address>
        <city>Barcelona</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de San Pedro de Alcantara</name>
      <address>
        <city>Caceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Mara√±on</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena; Servicio de Oncologia</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust - City Hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 10, 2018</study_first_submitted>
  <study_first_submitted_qc>September 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2018</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

